Use of PDE V inhibitors for improved fecundity in mammals
AssigneePfizer Inc.
InventorsSimon Lempriere Westbrook, Johannes Fridrich Zanzinger
Life of this patent
Estimating the term…
Abstract
The invention relates to the use of a cyclic guanosine 3′,5′-monophosphate phosphodiesterase type five (cGMP PDE V) inhibitor for increasing fecundity in a mammal by one or more of (a) promoting the growth of an oocyte, zygote, blastocyst, embryo and/or foetus, (b) increasing the rate or probability of survival of an embryo and/or foetus and (c) increasing the birth weight of a progeny, or for increasing milk productivity.
Claims2
A method of increasing fecundity in a female mammal by administering a cyclic guanosine 3′,5′-monophosphate phosphodiesterase type five (cGMP PDE V) inhibitor to (a) promote the growth of an oocyte, zygote, blastocyst, embryo and/or fetus;
- (b) increase the rate or probability of survival of an embryo and/or fetus;
- and (c) increase the birth weight of a progeny.
A method of increasing the survival rate or growth of a neonate born from a female mammal by administering a cyclic guanosine 3′,5′-monophosphate phosphodiesterase type five (cGMP PDE V) inhibitor to the female mammal.
Dependencies are inferred from the claim text.